Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190775 · ClinicalTrials.gov registry record · Phase 4
A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 502
- Enrollment target
NCT00190775 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 502 participants.
The verdict
NCT00190775, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 502 participants
- Enrollment target
Study Summary
This is a parallel design, double-blind, placebo-controlled, multi-center, 38-week treatment trial of atomoxetine in adults with attention deficit hyperactivity disorder (ADHD) who are currently living in a family situation with at least one child. The primary objective of the study is to demonstrate the efficacy of atomoxetine compared to placebo in the reduction of ADHD symptoms over 12 and 24 weeks of blinded treatment.
Interventions
- DRUG Placebo
- DRUG Atomoxetine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 502 participants |
| Start Date | 2004-09 |
| Est. Completion | 2009-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00190775
The ClinicalTrials.gov registry entry for NCT00190775 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 502 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00190775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00190775 about?
NCT00190775 is a clinical study titled "A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)". This is a parallel design, double-blind, placebo-controlled, multi-center, 38-week treatment trial of atomoxetine in adults with attention deficit hyperactivity disorder (ADHD) who are currently living in a family situation with at least one child. The primary objective of the study is to demonstrat...
What is the current status of trial NCT00190775?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 502 participants. The study started on 2004-09. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00190775?
The interventions under investigation include: Placebo (DRUG), Atomoxetine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00190775?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.